Osteoporosis Treatment in Patients with eGFR 39 mL/min
Rationale for Denosumab
- Denosumab is the preferred first-line osteoporosis medication for patients with eGFR 39 mL/min, as it requires no renal dose adjustment and has demonstrated efficacy and safety in this population, according to the American College of Rheumatology 1, 2
- Denosumab does not require dose adjustment for renal function and can be safely used when eGFR is between 30-60 mL/min, as recommended by the American College of Rheumatology 1, 3, 2
Critical Monitoring Requirements
- Ensure adequate calcium and vitamin D supplementation before initiating denosumab, with a target serum 25(OH)D level >30 ng/mL, as suggested by the American College of Rheumatology 2
- Monitor serum calcium and phosphorus at least monthly for the first 3 months, then every 3 months thereafter, according to the American College of Rheumatology 2
Why Not Bisphosphonates at eGFR 39?
- Bisphosphonates should generally not be used when eGFR <35 mL/min due to accumulation and potential toxicity, as stated by the American College of Rheumatology 1, 3
- The 2022 American College of Rheumatology guideline specifically states bisphosphonates should be avoided when eGFR <35 mL/min 3
Alternative Options
- PTH/PTHrP analogs (teriparatide, abaloparatide) require no renal dose adjustment and can be used at eGFR 39 mL/min, as recommended by the American College of Rheumatology 1, 3, 2
- After completing PTH/PTHrP therapy, patients require subsequent anti-resorptive therapy to prevent rapid bone loss, according to the American College of Rheumatology 3
Pre-Treatment Assessment Required
- Evaluate for chronic kidney disease-mineral and bone disorder (CKD-MBD) by measuring serum calcium, phosphate, PTH, and alkaline phosphatase, as suggested by the American College of Rheumatology 1, 2
- Assess for renal osteodystrophy and hyperparathyroidism using bone-specific alkaline phosphatase and intact PTH, according to the American College of Rheumatology 1, 2
Critical Safety Warning
- Denosumab requires continuous anti-resorptive therapy after discontinuation—stopping denosumab without transitioning to another medication causes rapid bone loss and increased vertebral fracture risk within 7-9 months, as warned by the American College of Rheumatology 3